Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm
View HTML
Toggle Summary Integra LifeSciences Announces Leadership Transition
Stuart Essig Appointed as Integra’s Next President and Chief Executive Officer Michael McBreen Appointed Chief Commercial Officer PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART), a leading global medical
View HTML
Toggle Summary Integra LifeSciences Reports First Quarter 2026 Financial Results
PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026. First Quarter 2026 Highlights First quarter revenues of $391.9
View HTML
Toggle Summary Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release,
View HTML
Toggle Summary Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company,
View HTML
Toggle Summary Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) --   Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on
View HTML
Toggle Summary Integra LifeSciences Announces Key Executive Leadership Appointments
Executive team further strengthened with appointments of Teshtar Elavia to the newly created chief technology officer role, Michael Hutchinson as chief legal officer, and Kerri DiPietro as chief quality officer, representing decades of experience in the MedTech industry PRINCETON, N.J., Feb.
View HTML
Toggle Summary Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with
View HTML
Toggle Summary Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P.
View HTML
Toggle Summary Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare
View HTML
Toggle Summary Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for
View HTML
Toggle Summary Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA ® Clarity Ultrasonic Surgical Aspirator System for cardiac surgeries.
View HTML
Toggle Summary Integra LifeSciences Reports Third Quarter 2025 Financial Results
PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1
View HTML
Toggle Summary Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings
View HTML
Toggle Summary Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post PRINCETON, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce its exhibition at the CNS Annual
View HTML